Rasna Therapeutics appoints new CEO
Rasna Therapeutics, the UK-based biotech that specialises in developing treatments for leukaemia, has announced the appointment of a new CEO. Dr Kunwar Shailubhai joins Rasna from Synergy Pharmaceuticals, where he had performed the role of CSO and, prior to this, Senior Vice President of Drug Discovery.
During his time at Synergy, Shailubhai led the development on Trulance all way through to FDA approval. Before this, he acted as research Specialist and Group Leader of the cancer chemoprevention group at Monsanto.
“Rasna’s focus on addressing the high unmet need that exists is a pressing challenge, with more than ten thousand deaths annually in the United States from acute myeloid leukemia,” commented Dr. Shailubhai on his appointment to the new role. “I look forward to taking on this challenge and progressing the powerful therapeutic approaches that Rasna has developed, which engage novel understanding of key mechanisms at the heart of disease biology.”
“We are delighted to welcome Kunwar into this role,” said Dr. Alessandro Padova, Chairman of Rasna Therapeutics, “He brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialization to market.”